Overexposed: Why it Might be Smarter to Play $2 Aleafia and Not Their Clinical Study Partner $200 Tilray The marijuana sector experienced a wild ride on Wednesday, but none more so than Tilray Inc. (NASDAQ: TLRY). The Canadian cannabis and pharmaceutical company recently made history when American regulatory... read more → September 20, 2018 Ryan T.
